The timing might strike some as curious. Just as Medicare Advantage plans across the country started pulling back—fewer offerings, tighter benefits, a growing sense that the gold rush may be cooling—Devoted Health decided to go all in.
The Waltham-based insurer closed a two-part Series F round totaling $366 million, the company confirmed. An initial $48 million landed in November 2025, followed by a much larger $317 million infusion this past January. Both tranches were led by The Space Between, working alongside Centricus, the London investment firm that manages somewhere north of $42 billion in assets.
For a company that already raised more than $2 billion before this round, the fresh capital isn't about survival. It's about scale. Devoted now counts over 466,000 members spread across 29 states—a 121% leap year-over-year that defies the broader market's deceleration. Whether that growth can be sustained, and at what cost, remains the open question.
When Wall Street Meets Main Street Medicine
The investor roster reads like a who's-who of healthcare's current moment. GV joined the latest round, as did Morgan Health, JPMorgan Chase's healthcare investment arm—a signal that institutional money still sees promise in tech-enabled Medicare models, even if the easy wins are behind us. VZVC, the new fund from former Andreessen Horowitz general partner Vijay Pande and partner Zack Werner, also participated.
Franklin Venture Partners, VanEck, and MIG Private Equity rounded out the newcomers. Existing backers—Cox Enterprises, Andreessen Horowitz, General Catalyst, Premji Invest—stuck around. Morgan Health's involvement feels particularly telling; the firm lists Devoted among its 2026 priorities, a public endorsement of the value-based care infrastructure thesis.
According to reports from Axios and S&P Global, Devoted's last major raise—a Series D in October 2021—pegged the company's valuation somewhere between $11.5 billion and $12.7 billion. The company declined to disclose current valuation figures. Given the choppier fundraising climate since then, that number likely shifted, though by how much remains unclear.
Growing Fast While Others Pull Back
Here's where Devoted's trajectory diverges from the pack. Between July 2024 and January 2026, membership more than doubled, climbing from roughly 227,000 to 466,000. The company expanded from 13 states in early 2024 to 29 today. Several of its plans earned 5-star and 4.5-star ratings in the 2026 CMS rankings—a meaningful achievement in an industry where quality metrics directly impact reimbursement.
This happened while the broader Medicare Advantage market tapped the brakes. Plan availability dropped about 6% year-over-year to 3,719 individual MA plans in 2025, according to KFF data. Average premiums stayed flat, but supplemental benefits—over-the-counter allowances, remote monitoring, the extras that differentiate plans—became less common. Traditional carriers appear to be tightening margins.
The contrast suggests two possibilities. Either Devoted found an operational edge that others missed, or it's spending aggressively to capture share before economics catch up. Probably both.
The Verticalization Gamble
What Devoted is actually building sits somewhere between an insurance company and a healthcare provider—an increasingly common strategy that nonetheless carries substantial execution risk. The company pairs its Medicare Advantage plans with Devoted Medical, an in-house care delivery operation that handles virtual visits, in-home services, and assigns each member a personal "Guide" to coordinate care.
All of this runs on Orinco, Devoted's proprietary platform that stitches payer and provider workflows into a single tech stack. It's the kind of integrated model that co-founders Ed and Todd Park—both athenahealth veterans—started sketching out back in 2017, when vertical integration in healthcare was more buzzword than proven playbook.
The clinical outcomes, at least on paper, support the approach. Devoted reported diabetes HbA1c control of at least 83% overall and hypertension control above 80% in 2023 metrics. U.S. News named it one of four "best overall" Medicare Advantage insurers for 2025.
Then again, managing chronic conditions for several hundred thousand members is a different beast than doing so for half a million or more. The company now employs over 2,000 people, though it did cut roughly 120 positions in June 2025, according to Becker's Payer Issues—a small reduction, but a reminder that hypergrowth rarely moves in a straight line.
The High-Wire Act Ahead
Devoted has been careful not to spell out exactly how it plans to spend the new capital, framing the raise instead around "sustaining rapid growth." Fair enough. But the Medicare Advantage landscape—now covering 54% of eligible beneficiaries—is simultaneously attractive and treacherous. Regulatory scrutiny is intensifying. Reimbursement pressures mount. The easy pickings are gone.
With a cumulative war chest exceeding $2.6 billion, Devoted is betting that verticalization and clinical quality will separate it from incumbents like UnitedHealthcare and Humana. That thesis has intuitive appeal. Integration should, in theory, reduce costs while improving care. The challenge lies in executing that theory at scale, across 29 states, with membership doubling annually.
Other high-flying health plans have stumbled on that same tightrope. Devoted's challenge now is proving it won't be one of them—while also, perhaps, keeping one eye on what an eventual exit might look like. Whether that's an IPO, a strategic acquisition, or something else entirely remains to be seen. For now, the company is placing another sizable bet that its model can withstand the squeeze traditional carriers are already feeling.
Sometimes those bets pay off. Sometimes they don't. The next 12 to 18 months should clarify which path Devoted is on.
